Zemprocitinib, a next-generation JAK1 inhibitor, may tame rheumatoid arthritis that does not respond to at least one biologic disease-modifying antirheumatic drug, a phase 3 clinical trial finds.
MarketBeat on MSN
Aclaris Therapeutics maps busy pipeline calendar, plans phase 2 asthma trial for ATI-052
Key Points Interested in Aclaris Therapeutics, Inc.? Here are five stocks we like better. Aclaris Therapeutics is preparing a ...
NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion ...
Investigators assessed parsaclisib for efficacy and safety in patients with myelofibrosis and suboptimal or declining response to stable ruxolitinib.
Turning $2 into $20,000 has never been easier — if you’re lucky. Some uncirculated U.S. $2 bills may be worth up to $20,000, but it depends on a few factors, according to Heritage Auctions, one of the ...
BACKGROUND: Congenital heart disease (CHD), the most common birth defect and a leading cause of infant mortality, is ...
A triple-targeted preclinical therapy combining daraxonrasib, afatinib, and SD36 drove durable pancreatic cancer regression ...
People who have type 2 diabetes have an increased amount of sugar in their blood, also called blood glucose. Increased blood sugar happens when your body’s insulin doesn’t work as well as it should.
Get your class on their feet and learning the 3 times table using Professor Pipette's fun song and movement routine. The 4 Times Table with Cyril the Swan. videoThe 4 Times Table with Cyril the Swan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results